

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYS6051 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Investigational New Drug (IND) application for SYS6051 (the “**Product**”), an antibody-drug conjugate developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. The Product also obtained approval from the National Medical Products Administration of the People’s Republic of China in April 2026 to conduct clinical trials in China.

The Product is a human tissue factor (TF)-targeted antibody-drug conjugate that binds to tissue factor expressed on the surface of tumor cells, entering the cells through endocytosis to release toxins and kill the tumor cells. The indication for this approval is advanced solid tumors. Preclinical studies demonstrated that the Product had good anti-tumor effects on a variety of cancers and is expected to exhibit favorable therapeutic effects in subsequent clinical trials.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 29 April 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.